Abstract
The safety and tolerability profile of nintedanib in the clinical setting is consistent with the product label
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Noth reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Genentech, personal fees from ImmuneWorks, personal fees from sanofi, outside the submitted work.
Conflict of interest: Dr. Oelberg has nothing to disclose.
Conflict of interest: Manika Kaul is an employee of Boehringer Ingelheim.Dr. Kaul reports and Manika Kaul is an employee of Boehringer Ingelheim.
Conflict of interest: Craig Conoscenti is an employee of Boehringer Ingelheim.Dr. Kaul reports and Manika Kaul is an employee of Boehringer Ingelheim.
Conflict of interest: Dr. RAGHU reports personal fees and other from Boerhinger-Ingelheim, other from BMS, other from Fibrogen, other from Gilead , other from Promedior, other from Roche-Genentech, personal fees and other from Sanofi, other from United Therapeutics, other from UCB, personal fees and other from Veracyte, outside the submitted work.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018